Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma

被引：2

作者：

Thompson, J. A.

Berman, D.

Siegal, J.

Minor, D.

Amin, A.

Ron, I.

Ridolfi, R.

Assi, H.

Hamid, O.

Weber, J.

机构：

[1] Seattle Canc Care Alliance, Seattle, WA USA

[2] Bristol Myers Squibb, Bristol, Avon, England

[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.9055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9055

引用

页数：1

共 50 条

[31] Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Queirolo, Paola
Spagnolo, Francesco
Ascierto, Paolo Antonio
Simeone, Ester
Marchetti, Paolo
Scoppola, Alessandro
Del Vecchio, Michele
Di Guardo, Lorenza
Maio, Michele
Di Giacomo, Anna Maria
Antonuzzo, Andrea
Cognetti, Francesco
Ferraresi, Virginia
Ridolfi, Laura
Guidoboni, Massimo
Guida, Michele
Pigozzo, Jacopo
Sileni, Vanna Chiarion
JOURNAL OF NEURO-ONCOLOGY, 2014, 118 (01) : 109 - 116
[32] Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Abid T. Javed
Kevin Batte
Mohamed Khalaf
Mustafa Abdul-Hussein
Pooja S. Elias
Donald O. Castell
BMC Gastroenterology, 19
[33] The efficacy and safety of ipilimumab in patients with advanced cutaneous or mucosal melanoma
Kosela-Paterczyk, Hanna
Wasylecka-Morawiec, Maja
Kozak, Katarzyna
Jagielska, Beata
Switaj, Tomasz
Rutkowski, Piotr
ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (05): : 256 - 262
[34] Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Treon, Steven P.
Gustine, Joshua
Meid, Kirsten
Yang, Guang
Xu, Lian
Liu, Xia
Demos, Maria
Kofides, Amanda
Tsakmaklis, Nicholas
Chen, Jiaji G.
Munshi, Manit
Chan, Gloria
Dubeau, Toni
Raje, Noopur
Yee, Andrew
O'Donnell, Elizabeth
Hunter, Zachary R.
Castillo, Jorge J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) : 2755 - +
[35] Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Javed, Abid T.
Batte, Kevin
Khalaf, Mohamed
Abdul-Hussein, Mustafa
Elias, Pooja S.
Castell, Donald O.
BMC GASTROENTEROLOGY, 2019, 19 (01)
[36] COST-EFFECTIVENESS OF IPILIMUMAB IN PREVIOUSLY TREATED PATIENTS FOR ADVANCED MELANOMA IN PORTUGAL
Radford, M.
Cortes, P.
Carrasco, J.
Gueron, B.
Goncalves, F.
VALUE IN HEALTH, 2013, 16 (03) : A139 - A139
[37] A community-based, real-world, study of treatment-naive advanced melanoma (AM) patients treated with 3 mg/kg ipilimumab (IPI) in the United States
Patt, D.
Wong, S. L.
Juday, T.
Penrod, J. R.
Chen, C.
Hebden, T.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S872 - S872
[38] Characterization of ipilimumab exposure-efficacy/safety response relationships in subjects with previously treated or untreated advanced melanoma.
Feng, Yan
Godfrey, C. J.
Chu, Hui-May
Masson, Eric
Williams, Daphne
Berman, David Mark
Roy, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] COMPARABLE EFFICACY AND SAFETY OF USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS PREVIOUSLY TREATED WITH SYSTEMIC THERAPIES AND TREATMENT NAIVE PATIENTS
Papp, K.
Kaufmann, R.
Toth, D. P.
Szapary, P.
Yeilding, N.
Li, S.
Wang, Y.
Gordon, K.
ACTA DERMATO-VENEREOLOGICA, 2009, 89 (05) : 588 - 588
[40] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean Jacques
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew Graham
Haanen, John B. A. G.
Maio, Michele
McArthur, Grant A.
Yang, Arvin
Rollin, Linda
Horak, Christine E.
Larkin, James M. G.
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)

← 1 2 3 4 5 →